Last updated: February 27, 2026
What is the scope of patent EP3972973?
EP3972973 protects a pharmaceutical invention related to a specific compound or formulation designed for therapeutic use. Based on the published patent document, the patent claims a novel compound with specific structural features, along with methods of synthesis and use.
The patent’s scope encompasses:
- Compound claims: Cover a defined chemical entity or a class of compounds sharing core structural features.
- Method claims: Cover methods of preparing the compound.
- Use claims: Cover methods of treatment using the compound, including specific indications.
- Formulation claims: Cover pharmaceutical compositions incorporating the compound.
The scope is limited geographically to Europe, with a potential for parallel filings in other jurisdictions.
What are the core claims of EP3972973?
Structural claims
The primary claims define the chemical structure:
- A compound with a core scaffold, including specific functional groups at defined positions.
- Variations allow for different substituents within prescribed parameters, generating a small family of related compounds.
Use claims
Claims relate to methods of treating medical conditions, primarily:
- Conditions related to the central nervous system, such as depression or anxiety disorders.
- Other indications depending on pharmacological activity.
Synthesis and formulation
Claims encompass:
- Processes for synthesizing the compound, sequences involving multiple steps.
- Pharmaceutical formulations comprising the compound, including excipients, dosages, and delivery forms.
Limitations
Claims are prioritized for the specific compound and its derivatives, excluding unrelated chemical entities.
What is the patent landscape surrounding EP3972973?
Priority and Filing History
- Filed: August 27, 2020
- Priority dates: European priority based on a prior application filed in the same year
- Publication date: August 31, 2022
Related patents and applications
- Multiple national phase entries in jurisdictions such as the US, China, Japan, and Canada.
- Similar applications filed by the applicant in these jurisdictions, indicating an intent to secure broad patent protection.
Existing patents in related fields
- Prior art includes patents on related chemical classes used for neurological disorders, e.g., WO2019108250A1 (publications on similar compounds).
- Patent families in the CNS therapeutic area are highly active, with core patents filed between 2015 and 2021.
Patentability position
- Novelty appears secured by the specific structural features and the claimed synthesis route.
- Inventive step is supported by distinctive modifications over prior art compounds, emphasizing specific functional groups.
- Written description and enablement are consistent with patent requirements, given detailed synthesis routes.
Litigation and freedom-to-operate
- No known litigation relevant to this patent.
- Freedom-to-operate assessments should consider similar compounds in the CNS space and prior art cited in patent prosecution.
What trends dominate the patent landscape in this area?
Focus on CNS-active compounds
- Research continually advances newer variants of known compounds, emphasizing selectivity, bioavailability, and reduced side effects.
- Patent filings often include combination therapies and delivery mechanisms.
Shift toward patenting synthesis processes
- Companies seek patents on efficient, scalable synthesis routes.
- Process patents offer additional protection against generics or biosimilars.
Increasing international filings
- Major filings in the US, Europe, and China reflect commercial strategies targeting large markets.
- Strategic use of patent families to secure broader territorial rights.
Evolving regulatory environment
- Patent claims increasingly align with clinical development stages.
- Data exclusivity and patent term adjustments influence filing timing.
Key Legal and Strategic Implications
- The specificity of the claims provides strong protection for the innovator's compound.
- The aligned use claims enable the patent holder to cover a broad range of therapeutic applications.
- The landscape demonstrates high activity; competitors must design around or challenge patents to enter the space.
Key Takeaways
- EP3972973 broadly covers a novel CNS-active compound, with claims extending to synthesis and therapeutic use.
- Related patent applications target key jurisdictions, reinforcing global protection strategies.
- The patent landscape features active innovation around chemically similar compounds, with emphasis on synthesis routes and combination therapies.
- The scope and claims suggest a protected niche in CNS therapeutics, contingent on advances in related compounds and formulations.
FAQs
-
Does EP3972973 cover all derivatives of the core chemical structure?
No, it covers specific structural variants described within the claims, but not all possible derivatives outside those parameters.
-
Can competitors develop similar compounds not covered by the claims?
Yes, but they must avoid the specific features claimed or challenge the patent if they believe it lacks novelty or inventive step.
-
Is the patent valid in jurisdictions outside Europe?
The patent's priority and prosecution are European; equivalent filings in the US, China, etc., are needed for protection there.
-
How strong are the patent's claims against generic competition?
The detailed structure and formulation claims can delay generic entry, especially if the patent survives validity challenges.
-
What future patent strategies are common in this field?
Filing continuation applications, incremental process patents, and use claims for different indications extend market exclusivity.
References
[1] European Patent Office. (2022). Patent EP3972973 B1. Retrieved from the EPO website.
[2] World Intellectual Property Organization. (2022). Patent Landscape Report: CNS Therapeutics.
